Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 59 articles:
HTML format
Text format



Single Articles


    June 2019
  1. ROYS A, Chang X, Liu Y, Xu X, et al
    Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer.
    Cancer Chemother Pharmacol. 2019 Jun 29. pii: 10.1007/s00280-019-03902.
    PubMed     Text format     Abstract available


  2. HOSOYA K, Fujimoto D, Kawachi H, Sato Y, et al
    Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2019 Jun 14. pii: 10.1007/s00280-019-03885.
    PubMed     Text format     Abstract available


  3. GOEL S, Swami U, Kumar K, Dittrich C, et al
    A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2019 Jun 12. pii: 10.1007/s00280-019-03877.
    PubMed     Text format     Abstract available


    May 2019
  4. LIN S, Nickens DJ, Patel M, Wilner KD, et al
    Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2019 May 24. pii: 10.1007/s00280-019-03861.
    PubMed     Text format     Abstract available


    April 2019
  5. CHEN J, Liu B, Zhang F, Cui W, et al
    Pharmacokinetics and safety of lobaplatin plus etoposide in Chinese men older than 65 years with extensive-stage small cell lung cancer: a phase II clinical trial.
    Cancer Chemother Pharmacol. 2019 Apr 30. pii: 10.1007/s00280-019-03828.
    PubMed     Text format     Abstract available


  6. LI Z, Wang M, Yu D, Luo W, et al
    Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2019 Apr 29. pii: 10.1007/s00280-019-03848.
    PubMed     Text format     Abstract available


  7. MISTRY HB, Helmlinger G, Al-Huniti N, Vishwanathan K, et al
    Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics.
    Cancer Chemother Pharmacol. 2019 Apr 24. pii: 10.1007/s00280-019-03840.
    PubMed     Text format     Abstract available


  8. KATO Y, Okuma Y, Watanabe K, Yomota M, et al
    A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2019 Apr 16. pii: 10.1007/s00280-019-03843.
    PubMed     Text format     Abstract available


  9. KIVRAK SALIM D, Akin Telli T, Tatli AM, Kilickap S, et al
    Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2019 Apr 9. pii: 10.1007/s00280-019-03839.
    PubMed     Text format     Abstract available


    March 2019
  10. KILICKAP S, Onder S, Dizdar O, Erman M, et al
    Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability.
    Cancer Chemother Pharmacol. 2019 Mar 12. pii: 10.1007/s00280-019-03810.
    PubMed     Text format     Abstract available


    February 2019
  11. KAWATA T, Higashimori M, Itoh Y, Tomkinson H, et al
    Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2019 Feb 14. pii: 10.1007/s00280-019-03788.
    PubMed     Text format     Abstract available


  12. YAMAGUCHI O, Kaira K, Mouri A, Shiono A, et al
    Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
    Cancer Chemother Pharmacol. 2019 Feb 13. pii: 10.1007/s00280-019-03790.
    PubMed     Text format     Abstract available


    December 2018
  13. GUSELLA M, Pasini F, Caruso D, Barile C, et al
    Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms.
    Cancer Chemother Pharmacol. 2018 Dec 12. pii: 10.1007/s00280-018-3751.
    PubMed     Text format     Abstract available


  14. QUAN YH, Lim JY, Choi BH, Choi Y, et al
    Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
    Cancer Chemother Pharmacol. 2018 Dec 4. pii: 10.1007/s00280-018-3737.
    PubMed     Text format     Abstract available


    October 2018
  15. HE Y, Xie H, Yu P, Jiang S, et al
    FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
    Cancer Chemother Pharmacol. 2018 Oct 9. pii: 10.1007/s00280-018-3697.
    PubMed     Text format     Abstract available


  16. ODA N, Hotta K, Ninomiya K, Minami D, et al
    A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
    Cancer Chemother Pharmacol. 2018 Oct 1. pii: 10.1007/s00280-018-3694.
    PubMed     Text format     Abstract available


    June 2018
  17. HUANG C, Liu S, Tong X, Fan H, et al
    Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications.
    Cancer Chemother Pharmacol. 2018 Jun 8. pii: 10.1007/s00280-018-3586.
    PubMed     Text format     Abstract available


    May 2018
  18. MORCOS PN, Nueesch E, Jaminion F, Guerini E, et al
    Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2018 May 10. pii: 10.1007/s00280-018-3597.
    PubMed     Text format     Abstract available


  19. IMAI H, Minemura H, Sugiyama T, Yamada Y, et al
    Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
    Cancer Chemother Pharmacol. 2018 May 8. pii: 10.1007/s00280-018-3596.
    PubMed     Text format     Abstract available


  20. KOBA T, Minami S, Nishijima-Futami Y, Masuhiro K, et al
    Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2018 May 4. pii: 10.1007/s00280-018-3598.
    PubMed     Text format     Abstract available


  21. SMIT EF, Garon EB, Reck M, Cappuzzo F, et al
    Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2018 May 2. pii: 10.1007/s00280-018-3560.
    PubMed     Text format     Abstract available


    April 2018
  22. FUJITA K, Uchida N, Kanai O, Okamura M, et al
    Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Cancer Chemother Pharmacol. 2018 Apr 19. pii: 10.1007/s00280-018-3585.
    PubMed     Text format     Abstract available


  23. NIHEI S, Sato J, Harada T, Kuyama S, et al
    Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab.
    Cancer Chemother Pharmacol. 2018 Apr 12. pii: 10.1007/s00280-018-3580.
    PubMed     Text format     Abstract available


  24. FUKUSHIMA T, Wakatsuki Y, Kobayashi T, Sonehara K, et al
    Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2018 Apr 11. pii: 10.1007/s00280-018-3573.
    PubMed     Text format     Abstract available


    February 2018
  25. CUI J, Wang MC, Zhang YM, Ren MZ, et al
    Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells.
    Cancer Chemother Pharmacol. 2018 Feb 26. pii: 10.1007/s00280-018-3539.
    PubMed     Text format     Abstract available


  26. SIENA L, Cipollina C, Di Vincenzo S, Ferraro M, et al
    Electrophilic derivatives of omega-3 fatty acids counteract lung cancer cell growth.
    Cancer Chemother Pharmacol. 2018 Feb 12. pii: 10.1007/s00280-018-3538.
    PubMed     Text format     Abstract available


    January 2018
  27. TAIRA T, Yoh K, Nagase S, Kubota K, et al
    Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2018 Jan 31. pii: 10.1007/s00280-018-3530.
    PubMed     Text format     Abstract available


  28. WANG S, Gao A, Liu J, Sun Y, et al
    First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
    Cancer Chemother Pharmacol. 2018 Jan 11. pii: 10.1007/s00280-017-3516.
    PubMed     Text format     Abstract available


  29. MATHERLY LH, Hou Z, Gangjee A
    The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.
    Cancer Chemother Pharmacol. 2018;81:1-15.
    PubMed     Text format     Abstract available


    December 2017
  30. FEDORCHUK O, Susak Y, Rudyk M, Senchylo N, et al
    Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells.
    Cancer Chemother Pharmacol. 2017 Dec 30. pii: 10.1007/s00280-017-3503.
    PubMed     Text format     Abstract available


  31. KATAOKA Y, Hirano K, Narabayashi T, Hara S, et al
    Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study.
    Cancer Chemother Pharmacol. 2017 Dec 11. pii: 10.1007/s00280-017-3498.
    PubMed     Text format     Abstract available


    November 2017
  32. MASUDA T, Hirano C, Horimasu Y, Nakashima T, et al
    The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Nov 15. doi: 10.1007/s00280-017-3476.
    PubMed     Text format     Abstract available


  33. SAKURAI R, Tomizawa Y, Yoshii A, Miura Y, et al
    A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Nov 9. doi: 10.1007/s00280-017-3439.
    PubMed     Text format     Abstract available


  34. SCHMID U, Liesenfeld KH, Fleury A, Dallinger C, et al
    Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
    Cancer Chemother Pharmacol. 2017 Nov 8. doi: 10.1007/s00280-017-3452.
    PubMed     Text format     Abstract available


  35. MURAKAMI S, Saito H, Kondo T, Ito H, et al
    Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Nov 7. doi: 10.1007/s00280-017-3460.
    PubMed     Text format     Abstract available


    October 2017
  36. CHEN K, Yu X, Wang H, Huang Z, et al
    Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2017 Oct 24. doi: 10.1007/s00280-017-3464.
    PubMed     Text format     Abstract available


  37. SRINIVASAN G, Sidhu GS, Williamson EA, Jaiswal AS, et al
    Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
    Cancer Chemother Pharmacol. 2017;80:861-867.
    PubMed     Text format     Abstract available


    September 2017
  38. ZHANG H, Hu B, Wang Z, Zhang F, et al
    miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
    Cancer Chemother Pharmacol. 2017 Sep 27. doi: 10.1007/s00280-017-3435.
    PubMed     Text format     Abstract available


  39. IKEZAWA Y, Asahina H, Oizumi S, Watanabe M, et al
    A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).
    Cancer Chemother Pharmacol. 2017 Sep 13. doi: 10.1007/s00280-017-3432.
    PubMed     Text format     Abstract available


  40. SATO J, Morikawa N, Chiba R, Nihei S, et al
    Case series on the association between blood levels and side effects of afatinib maleate.
    Cancer Chemother Pharmacol. 2017;80:545-553.
    PubMed     Text format     Abstract available


    August 2017
  41. REN K, Xu R, Huang J, Zhao J, et al
    Knockdown of long non-coding RNA KCNQ1OT1 depressed chemoresistance to paclitaxel in lung adenocarcinoma.
    Cancer Chemother Pharmacol. 2017;80:243-250.
    PubMed     Text format     Abstract available


    July 2017
  42. IMAI H, Sugiyama T, Tamura T, Minemura H, et al
    A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
    Cancer Chemother Pharmacol. 2017 Jul 31. doi: 10.1007/s00280-017-3403.
    PubMed     Text format     Abstract available


  43. KENMOTSU H, Ohde Y, Wakuda K, Nakashima K, et al
    Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Jul 31. doi: 10.1007/s00280-017-3400.
    PubMed     Text format     Abstract available


  44. ZHAO XM, Zhao J, Wu XH, Luo ZG, et al
    Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Cancer Chemother Pharmacol. 2017 Jul 28. doi: 10.1007/s00280-017-3399.
    PubMed     Text format     Abstract available


  45. KIM HK, Heo MH, Lee HS, Sun JM, et al
    Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Cancer Chemother Pharmacol. 2017 Jul 21. doi: 10.1007/s00280-017-3396.
    PubMed     Text format     Abstract available


  46. SHIROYAMA T, Tamiya M, Minami S, Takata S, et al
    Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study.
    Cancer Chemother Pharmacol. 2017 Jul 7. doi: 10.1007/s00280-017-3385.
    PubMed     Text format     Abstract available


    June 2017
  47. XU L, Fu Y, Li Y, Han X, et al
    Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells.
    Cancer Chemother Pharmacol. 2017 Jun 8. doi: 10.1007/s00280-017-3355.
    PubMed     Text format     Abstract available


  48. PARK S, Kang BW, Lee SJ, Yoon S, et al
    Clinical significance of systemic chemotherapy after curative resection of metachronous pulmonary metastases from colorectal cancer.
    Cancer Chemother Pharmacol. 2017 Jun 8. doi: 10.1007/s00280-017-3348.
    PubMed     Text format     Abstract available


  49. ASPESLAGH S, Shailubhai K, Bahleda R, Gazzah A, et al
    Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.
    Cancer Chemother Pharmacol. 2017;79:1257-1265.
    PubMed     Text format     Abstract available


    May 2017
  50. MILAKI G, Messaritakis I, Koinis F, Kotsakis A, et al
    Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 May 18. doi: 10.1007/s00280-017-3339.
    PubMed     Text format     Abstract available


  51. CHEN X, Liu L, Guo Z, Liang W, et al
    UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
    Cancer Chemother Pharmacol. 2017 May 13. doi: 10.1007/s00280-017-3306.
    PubMed     Text format     Abstract available


  52. OKUDA Y, Sato K, Sudo K, Hasegawa Y, et al
    Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
    Cancer Chemother Pharmacol. 2017;79:1013-1020.
    PubMed     Text format     Abstract available


    April 2017
  53. FUJIWARA T, Kenmotsu H, Naito T, Kawamura T, et al
    The incidence and risk factors of febrile neutropenia in chemotherapy-naive lung cancer patients receiving etoposide plus platinum.
    Cancer Chemother Pharmacol. 2017 Apr 28. doi: 10.1007/s00280-017-3324.
    PubMed     Text format     Abstract available


  54. NISHIJIMA-FUTAMI Y, Minami S, Futami S, Koba T, et al
    Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Apr 28. doi: 10.1007/s00280-017-3321.
    PubMed     Text format     Abstract available


  55. LAU YY, Gu W, Lin T, Viraswami-Appanna K, et al
    Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Apr 19. doi: 10.1007/s00280-017-3308.
    PubMed     Text format     Abstract available


  56. XIANG T, Kang X, Gong Z, Bai W, et al
    XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.
    Cancer Chemother Pharmacol. 2017;79:791-800.
    PubMed     Text format     Abstract available


    March 2017
  57. WAKELEE HA, Gettinger S, Engelman J, Janne PA, et al
    A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Mar 28. doi: 10.1007/s00280-017-3283.
    PubMed     Text format     Abstract available


  58. JANG J, Kim HK, Cho BC, Lee KH, et al
    Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Mar 24. doi: 10.1007/s00280-017-3289.
    PubMed     Text format     Abstract available


  59. MORCOS PN, Bogman K, Hubeaux S, Sturm-Pellanda C, et al
    Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies.
    Cancer Chemother Pharmacol. 2017;79:559-568.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: